A Study of Lu AF82422 in Participants With Multiple System Atrophy

Key Inclusion Criteria: * The participant is diagnosed with possible or probable MSA of the multiple system atrophy parkinsonian type (MSA-P) or multiple system atrophy cerebellar type (MSA-C) sub-type at the Screening Visit. * The participant had onset of motor and/or autonomic (orthostatic or urinary) MSA symptoms within 5 years prior to the Screening Visit in the judgement of the investigator. * The participant has an UMSARS Part I score ≤16 (omitting item 11 on sexual function) at the Screening Visit. * The participant has a cognitive performance evaluated by the Montreal Cognitive Assessment (MoCA) with a score ≥22 at the Screening Visit. Open-label Extension Entry Criteria * The participant has completed the EoT Visit and did not withdraw in the DBP. * The participant has consented to participate in the OLE. * The participant has completed the DBP within the last 5 months and will be enrolled into the OLE no later than end of Q1 2024. * The participant is, in the Investigator's opinion, likely to comply with the protocol. * The participant has not received any other Investigational product since the EOoTDBP Visit. Key Exclusion Criteria: * The participant has been treated with an anti-α-synuclein monoclonal antibody, mesenchymal stem cells or an inhibitor of α-synuclein aggregation within the last 12 months. * The participant has any past or current treatment with an active vaccine targeting α-synuclein. * The participant has 2 or more blood relatives with a histor…